CeriBell (NASDAQ:CBLL) CFO Scott Blumberg Sells 808 Shares of Stock

CeriBell, Inc. (NASDAQ:CBLL) CFO Scott Blumberg sold 808 shares of CeriBell stock in a transaction that occurred on Monday, February 23rd. The shares were sold at an average price of $19.79, for a total transaction of $15,990.32. Following the completion of the transaction, the chief financial officer directly owned 118,334 shares in the company, valued at approximately $2,341,829.86. The trade was a 0.68% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Scott Blumberg also recently made the following trade(s):

• On Monday, December 22nd, Scott Blumberg sold 36,000 shares of CeriBell stock. The stock was sold at an average price of $21.00, for a total transaction of $756,000.00.

CeriBell Stock Down 0.5%

Shares of NASDAQ:CBLL traded down $0.09 during midday trading on Thursday, reaching $18.86. 143,858 shares of the company were exchanged, compared to its average volume of 345,803. The firm has a market cap of $699.71 million, a PE ratio of -12.83 and a beta of 1.03. CeriBell, Inc. has a fifty-two week low of $10.01 and a fifty-two week high of $25.37. The stock has a fifty day simple moving average of $21.20 and a two-hundred day simple moving average of $16.19. The company has a quick ratio of 12.25, a current ratio of 12.65 and a debt-to-equity ratio of 0.12.

CeriBell (NASDAQ:CBLL) last released its quarterly earnings results on Tuesday, February 24th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.43) by $0.07. The firm had revenue of $24.78 million for the quarter, compared to the consensus estimate of $23.95 million. CeriBell had a negative return on equity of 30.99% and a negative net margin of 59.97%. As a group, sell-side analysts forecast that CeriBell, Inc. will post -2.46 earnings per share for the current year.

Trending Headlines about CeriBell

Here are the key news stories impacting CeriBell this week:

• Positive Sentiment: Q4 beat on EPS and revenue — CeriBell reported Q4 EPS of ($0.36) vs. a consensus of ($0.43) and revenue of $24.78M vs. $23.95M expected, a beat that supports the recent uptick in the share price. MarketBeat: Q4 Results & Conference Call
• Positive Sentiment: FY‑2026 revenue guidance provided — Management gave revenue guidance of roughly $111M–$115M for FY‑2026, which is close to consensus (~$112.7M), offering a clearer growth target for the year. Business Insider: Full Year Results & Guidance
• Positive Sentiment: Earnings call highlighted revenue surge and market expansion — Management commentary and the call transcript emphasized accelerating revenue and expansion into new markets, supporting upside potential if execution continues. Yahoo Finance: Q4 2025 Earnings Call Highlights
• Neutral Sentiment: Short‑interest data appears unreliable this cycle — the published short‑interest entry shows zero shares / NaN change, which is likely a reporting artifact and provides no actionable signal today.
• Negative Sentiment: Multiple insider sales disclosed — several senior executives (CEO Xingjuan Chao, CFO Scott Blumberg, CTO Raymond Woo, CRO Joseph Manni and a VP) sold small amounts of stock at roughly $19.79–$19.98, reducing their positions by fractions of a percent; while sizes are modest relative to total holdings, clustered insider selling can create short‑term investor concern. InsiderTrades: Xingjuan Chao Sale SEC Filing: CEO Ownership

Institutional Investors Weigh In On CeriBell

Institutional investors and hedge funds have recently modified their holdings of the company. Squarepoint Ops LLC acquired a new position in CeriBell during the second quarter worth approximately $1,054,000. Geode Capital Management LLC increased its holdings in shares of CeriBell by 55.4% during the 2nd quarter. Geode Capital Management LLC now owns 447,936 shares of the company’s stock worth $8,391,000 after acquiring an additional 159,698 shares during the last quarter. Emerald Mutual Fund Advisers Trust raised its stake in CeriBell by 58.2% in the 3rd quarter. Emerald Mutual Fund Advisers Trust now owns 155,360 shares of the company’s stock valued at $1,785,000 after acquiring an additional 57,175 shares during the period. Police & Firemen s Retirement System of New Jersey raised its stake in CeriBell by 161.0% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 5,677 shares of the company’s stock valued at $106,000 after acquiring an additional 3,502 shares during the period. Finally, F m Investments LLC acquired a new stake in CeriBell during the 2nd quarter valued at $381,000.

Wall Street Analyst Weigh In

CBLL has been the topic of a number of recent research reports. BTIG Research reiterated a “buy” rating and issued a $30.00 price objective on shares of CeriBell in a report on Wednesday, January 28th. Canaccord Genuity Group boosted their price target on shares of CeriBell from $29.00 to $30.00 and gave the stock a “buy” rating in a research report on Wednesday, December 17th. TD Cowen restated a “buy” rating on shares of CeriBell in a report on Tuesday, December 9th. Finally, JPMorgan Chase & Co. dropped their target price on CeriBell from $21.00 to $17.00 and set an “overweight” rating on the stock in a report on Wednesday, November 5th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $24.67.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.